Fair enough in concept. FDA doesn't agree with you

Quote:

---

Fair enough in concept. FDA doesn't agree with your assessment of CD10. They say it failed to meet both primary and secondary.

---

Tell us what the purpose of a phase 2 trial is. We didn't meet the endpoints because of a protocol that allowed low score zero score patients into the trial. Even with the data we had we could have got a phase 3.

Quote:

---

Jury still out on Longhauler and Nash.

---

NASH we don't have the data. In longhaulers our data is more than good enough for a phase 3 which is what determines whether a phase 2 is successful since that's it's primary purpose.